Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Ver en el sistema de origen Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508914867994624 |
|---|---|
| author | Mina C. Hosseinipour Gregory P. Bisson Sachiko Miyahara Xin Sun Agnes Moses Cynthia Riviere Fredrick K Kirui Sharlaa Badal‐Faesen David Lagat Mulinda Nyirenda Kogieleum Naidoo James Hakim Peter Mugyenyi Germán Henostroza Paul Leger Javier R. Lama Lerato Mohapi Jorge Alave Vidya Mave Valdiléa G. Veloso Sandy Pillay Nagalingeswaran Kumarasamy Jing Bao Evelyn Hogg Lynne Jones Andrew Zolopa Johnstone Kumwenda Amita Gupta |
| author_browse | Agnes Moses Amita Gupta Andrew Zolopa Cynthia Riviere David Lagat Evelyn Hogg Fredrick K Kirui Germán Henostroza Gregory P. Bisson James Hakim Javier R. Lama Jing Bao Johnstone Kumwenda Jorge Alave Kogieleum Naidoo Lerato Mohapi Lynne Jones Mina C. Hosseinipour Mulinda Nyirenda Nagalingeswaran Kumarasamy Paul Leger Peter Mugyenyi Sachiko Miyahara Sandy Pillay Sharlaa Badal‐Faesen Valdiléa G. Veloso Vidya Mave Xin Sun |
| author_facet | Mina C. Hosseinipour Gregory P. Bisson Sachiko Miyahara Xin Sun Agnes Moses Cynthia Riviere Fredrick K Kirui Sharlaa Badal‐Faesen David Lagat Mulinda Nyirenda Kogieleum Naidoo James Hakim Peter Mugyenyi Germán Henostroza Paul Leger Javier R. Lama Lerato Mohapi Jorge Alave Vidya Mave Valdiléa G. Veloso Sandy Pillay Nagalingeswaran Kumarasamy Jing Bao Evelyn Hogg Lynne Jones Andrew Zolopa Johnstone Kumwenda Amita Gupta |
| author_sort | Mina C. Hosseinipour |
| collection | Producción científica |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/659 |
| institution | UPeU |
| language | English |
| publishDate | 2016 |
| publishDateRange | 2016 |
| publishDateSort | 2016 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/6592026-10-30T16:14:45ZEmpirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trialMina C. HosseinipourGregory P. BissonSachiko MiyaharaXin SunAgnes MosesCynthia RiviereFredrick K KiruiSharlaa Badal‐FaesenDavid LagatMulinda NyirendaKogieleum NaidooJames HakimPeter MugyenyiGermán HenostrozaPaul LegerJavier R. LamaLerato MohapiJorge AlaveVidya MaveValdiléa G. VelosoSandy PillayNagalingeswaran KumarasamyJing BaoEvelyn HoggLynne JonesAndrew ZolopaJohnstone KumwendaAmita GuptaMedicineTuberculosisIsoniazidInternal medicineClinical endpointPopulationRandomized controlled trialPediatricsEnvironmental healthPathologyMedicineTuberculosisIsoniazidInternal medicineClinical endpointPopulationRandomized controlled trialPediatricsEnvironmental healthPathologyAdultAdultAdultAmbulatory Care FacilitiesAmbulatory Care FacilitiesAmbulatory Care FacilitiesAntitubercular Agents therapeutic useAntitubercular Agents therapeutic useAntitubercular Agents therapeutic useFemaleFemaleFemaleHumansHumansHumansIsoniazid therapeutic useIsoniazid therapeutic useIsoniazid therapeutic useMaleMaleMaleTuberculosis immunologyTuberculosis immunologyTuberculosis immunologyTuberculosis prevention & controlTuberculosis prevention & controlTuberculosis prevention & controlHIV Infections drug therapyHIV Infections drug therapyHIV Infections drug therapyHIV Infections immunologyHIV Infections immunologyHIV Infections immunologyTreatment OutcomeTreatment OutcomeTreatment OutcomeAIDS-Related Opportunistic Infections immunologyAIDS-Related Opportunistic Infections immunologyAIDS-Related Opportunistic Infections immunologyAIDS-Related Opportunistic Infections prevention & controlAIDS-Related Opportunistic Infections prevention & controlAIDS-Related Opportunistic Infections prevention & controlCD4 Lymphocyte CountCD4 Lymphocyte CountCD4 Lymphocyte CountAnti-HIV Agents therapeutic useAnti-HIV Agents therapeutic useAnti-HIV Agents therapeutic useKaplan-Meier EstimateKaplan-Meier EstimateKaplan-Meier EstimateHealth Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatmentHealth Sciences Medicine Infectious Diseases Tuberculosis Research and EpidemiologyHealth Sciences Medicine Infectious Diseases HIV/AIDS Research and InterventionsArticlehttps://pubmed.ncbi.nlm.nih.gov/27025337https://arca.fiocruz.br/handle/icict/2933910.1016/s0140-6736(16)00546-8https://hdl.handle.net/20.500.15037/659W2298765190enThe Lancet0140-67361474-547X2016-03-012026-06-13T09:29:24Z2026-06-13T09:29:24Z |
| spellingShingle | Medicine Tuberculosis Isoniazid Internal medicine Clinical endpoint Population Randomized controlled trial Pediatrics Environmental health Pathology Medicine Tuberculosis Isoniazid Internal medicine Clinical endpoint Population Randomized controlled trial Pediatrics Environmental health Pathology Adult Adult Adult Ambulatory Care Facilities Ambulatory Care Facilities Ambulatory Care Facilities Antitubercular Agents therapeutic use Antitubercular Agents therapeutic use Antitubercular Agents therapeutic use Female Female Female Humans Humans Humans Isoniazid therapeutic use Isoniazid therapeutic use Isoniazid therapeutic use Male Male Male Tuberculosis immunology Tuberculosis immunology Tuberculosis immunology Tuberculosis prevention & control Tuberculosis prevention & control Tuberculosis prevention & control HIV Infections drug therapy HIV Infections drug therapy HIV Infections drug therapy HIV Infections immunology HIV Infections immunology HIV Infections immunology Treatment Outcome Treatment Outcome Treatment Outcome AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections prevention & control AIDS-Related Opportunistic Infections prevention & control AIDS-Related Opportunistic Infections prevention & control CD4 Lymphocyte Count CD4 Lymphocyte Count CD4 Lymphocyte Count Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Kaplan-Meier Estimate Kaplan-Meier Estimate Kaplan-Meier Estimate Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Health Sciences Medicine Infectious Diseases Tuberculosis Research and Epidemiology Health Sciences Medicine Infectious Diseases HIV/AIDS Research and Interventions Mina C. Hosseinipour Gregory P. Bisson Sachiko Miyahara Xin Sun Agnes Moses Cynthia Riviere Fredrick K Kirui Sharlaa Badal‐Faesen David Lagat Mulinda Nyirenda Kogieleum Naidoo James Hakim Peter Mugyenyi Germán Henostroza Paul Leger Javier R. Lama Lerato Mohapi Jorge Alave Vidya Mave Valdiléa G. Veloso Sandy Pillay Nagalingeswaran Kumarasamy Jing Bao Evelyn Hogg Lynne Jones Andrew Zolopa Johnstone Kumwenda Amita Gupta Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial |
| title | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial |
| title_full | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial |
| title_fullStr | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial |
| title_full_unstemmed | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial |
| title_short | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial |
| title_sort | empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced hiv initiating antiretroviral therapy remember a multicountry open label randomised controlled trial |
| topic | Medicine Tuberculosis Isoniazid Internal medicine Clinical endpoint Population Randomized controlled trial Pediatrics Environmental health Pathology Medicine Tuberculosis Isoniazid Internal medicine Clinical endpoint Population Randomized controlled trial Pediatrics Environmental health Pathology Adult Adult Adult Ambulatory Care Facilities Ambulatory Care Facilities Ambulatory Care Facilities Antitubercular Agents therapeutic use Antitubercular Agents therapeutic use Antitubercular Agents therapeutic use Female Female Female Humans Humans Humans Isoniazid therapeutic use Isoniazid therapeutic use Isoniazid therapeutic use Male Male Male Tuberculosis immunology Tuberculosis immunology Tuberculosis immunology Tuberculosis prevention & control Tuberculosis prevention & control Tuberculosis prevention & control HIV Infections drug therapy HIV Infections drug therapy HIV Infections drug therapy HIV Infections immunology HIV Infections immunology HIV Infections immunology Treatment Outcome Treatment Outcome Treatment Outcome AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections prevention & control AIDS-Related Opportunistic Infections prevention & control AIDS-Related Opportunistic Infections prevention & control CD4 Lymphocyte Count CD4 Lymphocyte Count CD4 Lymphocyte Count Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Kaplan-Meier Estimate Kaplan-Meier Estimate Kaplan-Meier Estimate Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Health Sciences Medicine Infectious Diseases Tuberculosis Research and Epidemiology Health Sciences Medicine Infectious Diseases HIV/AIDS Research and Interventions |
| topic_facet | Medicine Tuberculosis Isoniazid Internal medicine Clinical endpoint Population Randomized controlled trial Pediatrics Environmental health Pathology Medicine Tuberculosis Isoniazid Internal medicine Clinical endpoint Population Randomized controlled trial Pediatrics Environmental health Pathology Adult Adult Adult Ambulatory Care Facilities Ambulatory Care Facilities Ambulatory Care Facilities Antitubercular Agents therapeutic use Antitubercular Agents therapeutic use Antitubercular Agents therapeutic use Female Female Female Humans Humans Humans Isoniazid therapeutic use Isoniazid therapeutic use Isoniazid therapeutic use Male Male Male Tuberculosis immunology Tuberculosis immunology Tuberculosis immunology Tuberculosis prevention & control Tuberculosis prevention & control Tuberculosis prevention & control HIV Infections drug therapy HIV Infections drug therapy HIV Infections drug therapy HIV Infections immunology HIV Infections immunology HIV Infections immunology Treatment Outcome Treatment Outcome Treatment Outcome AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections immunology AIDS-Related Opportunistic Infections prevention & control AIDS-Related Opportunistic Infections prevention & control AIDS-Related Opportunistic Infections prevention & control CD4 Lymphocyte Count CD4 Lymphocyte Count CD4 Lymphocyte Count Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Anti-HIV Agents therapeutic use Kaplan-Meier Estimate Kaplan-Meier Estimate Kaplan-Meier Estimate Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment Health Sciences Medicine Infectious Diseases Tuberculosis Research and Epidemiology Health Sciences Medicine Infectious Diseases HIV/AIDS Research and Interventions |
| url | https://pubmed.ncbi.nlm.nih.gov/27025337 https://arca.fiocruz.br/handle/icict/29339 https://hdl.handle.net/20.500.15037/659 |
| work_keys_str_mv | AT minachosseinipour empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT gregorypbisson empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT sachikomiyahara empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT xinsun empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT agnesmoses empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT cynthiariviere empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT fredrickkkirui empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT sharlaabadalfaesen empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT davidlagat empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT mulindanyirenda empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT kogieleumnaidoo empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT jameshakim empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT petermugyenyi empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT germanhenostroza empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT paulleger empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT javierrlama empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT leratomohapi empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT jorgealave empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT vidyamave empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT valdileagveloso empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT sandypillay empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT nagalingeswarankumarasamy empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT jingbao empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT evelynhogg empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT lynnejones empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT andrewzolopa empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT johnstonekumwenda empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial AT amitagupta empiricaltuberculosistherapyversusisoniazidinadultoutpatientswithadvancedhivinitiatingantiretroviraltherapyrememberamulticountryopenlabelrandomisedcontrolledtrial |